Anbio BiotechnologyNNNN -2.96%24 Return-on-Tangible-Equity is 18.06% as of Dec. 2025, which is 33% below its 10-year median of 27.05. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 757 Medical Devices & Instruments companies, Anbio Biotechnology ranks better than 87.05% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Anbio Biotechnology's annualized net income for the quarter that ended in Dec. 2025 was $5.21 Mil. Anbio Biotechnology's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $28.85 Mil. Therefore, Anbio Biotechnology's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 18.06%.
The historical rank and industry rank for Anbio Biotechnology's Return-on-Tangible-Equity or its related term are showing as below:
NNNN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 14.83 Med: 27.05 Max: 132.75
Current: 25.65
During the past 5 years, Anbio Biotechnology's highest Return-on-Tangible-Equity was 132.75%. The lowest was 14.83%. And the median was 27.05%.
NNNN's Return-on-Tangible-Equity is ranked better than 87.05% of 757
companies
in the Medical Devices & Instruments industry
Industry Median: 4.09
vs NNNN: 25.65
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Anbio Biotechnology Return-on-Tangible-Equity Related Terms
Anbio Biotechnology Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NNNN vs ANGO, OSUR, UTMD: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 18.06% mean?
Anbio Biotechnology (NNNN) has a Return-on-Tangible-Equity of 18.06% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Anbio Biotechnology and its competitors. This is 33% below median its historical median of 27.05. Over the past decade, Anbio Biotechnology's Return-on-Tangible-Equity has ranged from 14.83 to 132.75. According to the industry distribution chart, Anbio Biotechnology ranks #98 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 12.9%.
Is Anbio Biotechnology's Return-on-Tangible-Equity too high?
Anbio Biotechnology's current Return-on-Tangible-Equity of 18.06% is 33% below median its 10-year median of 27.05. Over the past 10 years, this metric has ranged from a low of 14.83 to a high of 132.75. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.09. Anbio Biotechnology's value of 18.06% is 341.6% above this industry median. Based on the distribution chart, Anbio Biotechnology ranks #98 out of 757 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's Return-on-Tangible-Equity compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #98 out of 757 companies for Return-on-Tangible-Equity. This places Anbio Biotechnology in the top 13% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.09. Anbio Biotechnology's value of 18.06% is 341.6% above this benchmark. Historically, Anbio Biotechnology's own Return-on-Tangible-Equity has ranged from 14.83 to 132.75 over the past decade. While the company's 10-year median is 27.05 vs. the industry median of 4.09, Anbio Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.09, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current Return-on-Tangible-Equity of 18.06% is 341.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current Return-on-Tangible-Equity is 18.06%, which is 33% below median its own 10-year median of 27.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current Return-on-Tangible-Equity of 18.06%. The current Return-on-Tangible-Equity is 18.06%, which is 33% below median its 10-year median of 27.05 and 341.6% above the Medical Devices & Instruments industry median of 4.09. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current Return-on-Tangible-Equity is 18.06% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
